Cargando…

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer

Endometrial Cancer (EC) is an important cause of death in women worldwide. Despite early diagnosis and optimal treatment of localized disease, relapsed patients have few therapeutic options because after first line therapy, currently no standard of care exists. On the basis of endocrine positivity o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giannone, Gaia, Tuninetti, Valentina, Ghisoni, Eleonora, Genta, Sofia, Scotto, Giulia, Mittica, Gloria, Valabrega, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539322/ https://www.ncbi.nlm.nih.gov/pubmed/31083638 http://dx.doi.org/10.3390/ijms20092353

Ejemplares similares

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Role of Mediterranean diet in preventing platinum based gastrointestinal toxicity in gynecolocological malignancies: A single Institution experience
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
por: Mittica, Gloria, et al.
Publicado: (2016)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

Androgen receptor status predicts development of brain metastases in ovarian cancers
por: Mittica, Gloria, et al.
Publicado: (2017)

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018)

Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
por: Valabrega, Giorgio, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)

Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
por: Turinetto, Margherita, et al.
Publicado: (2022)

Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
por: Tanaka, Tomohito, et al.
Publicado: (2017)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
por: Tuninetti, Valentina, et al.
Publicado: (2023)

Ovarian Cancer Immunotherapy: Turning up the Heat
por: Ghisoni, Eleonora, et al.
Publicado: (2019)

The Renaissance of Cyclin Dependent Kinase Inhibitors
por: Ettl, Tobias, et al.
Publicado: (2022)

Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020)

Lynch syndrome-associated endometrial cancer patient with a rare novel germline likely pathogenic variant of MSH2 gene: A case report
por: Zumstein, L., et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study
por: Tuninetti, Valentina, et al.
Publicado: (2023)

The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer
por: Chiarle, Roberto, et al.
Publicado: (2001)

Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action
por: Łukasik, Paweł, et al.
Publicado: (2021)

Cyclin-dependent kinases
por: Malumbres, Marcos
Publicado: (2014)

Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells
por: LIU, WEN-XIN, et al.
Publicado: (2015)

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)

Cyclin-Dependent Kinase Inhibitors Induce Apoptosis in Plant Cells
por: Strnad, M., et al.
Publicado: (2001)

Purine Inhibitors of Cyclin-Dependent Kinase and Their Apoptosis and Cytotoxicity Mechanisms
por: Strnad, M., et al.
Publicado: (2001)

Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020)

Cyclin-dependent kinases govern formation and maintenance of the nucleolus
por: Sirri, Valentina, et al.
Publicado: (2002)

The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
por: Javed, Aadil, et al.
Publicado: (2023)

Functional Differentiation of Cyclins and Cyclin-Dependent Kinases in Giardia lamblia
por: Kim, Juri, et al.
Publicado: (2023)

Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy
por: Ullah, Zakir, et al.
Publicado: (2009)

Efficient Activation of Reconstructed Rat Embryos by Cyclin-Dependent Kinase Inhibitors
por: Webb, Robin L., et al.
Publicado: (2010)

Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors
por: Suthar, M. P., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ctdqfsaseu7gofn3v8q8f4lqkf